Efficacy and Safety of Romiplostim N01 Combined With Rituximab in Patients With Oral TPO-RA-Refractory Primary Immune Thrombocytopenia

• Status: RECRUITING
• Trial end date: 2027-07-31

Summary

The primary objective of this trial is to assess the efficacy and safety of combining Romiplostim N01 with Rituximab for the treatment of adult patients with primary immune thrombocytopenia (ITP) whose disease is refractory to oral TPO-RAs.

All participants in this study will receive the same combination treatment:

Rituximab: Given once a week through an intravenous infusion for 4 weeks. Romiplostim N01: Given as a weekly injection for 12 weeks. The dose may be adjusted each week based on the patient's platelet count.

Participants will be asked to:

Visit the clinic regularly for check-ups, blood tests (to monitor platelet counts), and safety assessments.

Report their bleeding symptoms for evaluation. This is an open-label, single-arm trial, meaning that all participants will receive the investigational treatment, and both the research team and participants will be aware of the treatment assigned. The study aims to enroll approximately 30 adult patients aged 14 years or older who have been diagnosed with ITP and have not responded adequately to prior oral TPO-RAs (eltrombopag/hetrombopag).

• Phase: NA

Details

• Lead Sponsor: The First Affiliated Hospital of Soochow University
• Treatments: Rituximab